25/03/2008
ReGen Therapeutics Plc (‘ReGen’ or the ‘Company’, AIM: RGT) is pleased to announce that the Ministry of Health of the Republic of Cyprus has approved the importation and sale of its nutritional supplement ColostrininTM by its Cypriot licensee Golgi Pharmaceuticals Ltd.*
To date ColostrininTM is marketed in the US, Canada and Australia under the brand name CogniSureTM as a nutritional supplement to ‘support healthy brain aging and cognition in humans’**.
Commenting on this, the first approval to sell ColostrininTM in a territory of the European Union, Percy Lomax, Chairman and Chief Executive Officer of ReGen said:
“Cyprus is a member of the European Union which, with the US and Japan, is one of the three key target areas for ColostrininTM. ReGen will now be working with Golgi to launch the product in Cyprus as soon as possible. Currently, we believe a launch date towards the end of the 2nd quarter is possible.”
* Golgi Pharmaceuticals Ltd is a distributor of pharmaceuticals and nutraceuticals in the Republic of Cyprus. (email address of Golgi Pharmaceuticals Ltd – golgipha@cytanet.com.cy)
**ColostrininTM for use as a human nutraceutical is licensed in North America and Australasia to Metagenics Inc. of San Clemente, California (www.metagenics.com). Discussions are ongoing with potential distributors in other regions of the world.
For further information:
Percy Lomax
ReGen Therapeutics Plc
Tel No 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel No 020 7628 3396